BrainsWay Ltd. (BWAY) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

BrainsWay Ltd. (BWAY) Healthcare & Pipeline Overview

BrainsWay Ltd. leverages advanced neurostimulation technology to address a wide range of mental health disorders, positioning itself as a leader in the medical devices sector with a strong focus on noninvasive treatments.

What Is the Investment Thesis for BWAY?

BrainsWay Ltd. presents a compelling investment thesis driven by its unique position in the mental health treatment market. With a market capitalization of $595M and a profit margin of 14.6%, the company demonstrates strong financial health. The gross margin of 75.5% reflects its operational efficiency and the premium nature of its dTMS technology. As mental health disorders become increasingly prevalent, BrainsWay is well-positioned to capture market share, particularly in the U.S. and European markets, where demand for innovative treatment options is growing. Additionally, the company's ongoing research initiatives may lead to new product offerings, further enhancing its revenue potential. However, investors should remain cognizant of potential regulatory hurdles and competition within the medical devices sector, which may impact growth trajectories.

Based on FMP financials and quantitative analysis

BWAY Key Highlights

Market capitalization of $595M reflects a solid market presence in the neurostimulation sector.

• Profit margin of 14.6% indicates effective cost management and operational efficiency.
• Gross margin of 75.5% showcases the premium pricing strategy and high demand for its products.
• P/E ratio of 79.3 suggests strong growth expectations from investors despite current profitability.
• Beta of 0.22 indicates lower volatility compared to the broader market, appealing to risk-averse investors.

Who Are BWAY's Competitors?

BWAY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BWAY's Key Strengths?

Innovative technology with proven efficacy in treating mental health disorders.

• Strong gross margins indicating operational efficiency and pricing power.
• Established market presence across the U.S., Europe, and Israel.
• Experienced management team with a track record in the healthcare sector.

What Are BWAY's Weaknesses?

Limited brand recognition compared to larger competitors.

• Dependence on a narrow product line focused on neurostimulation.
• Potential regulatory hurdles that could delay product approvals.
• No dividend payouts may deter income-focused investors.

What Could Drive BWAY Stock Higher?

Expansion into new international markets to increase product adoption.

• Development of additional applications for dTMS technology targeting new mental health disorders.
• Strategic partnerships with healthcare providers to enhance clinical trial capabilities.
• Anticipated regulatory approvals for new treatment indications in key markets.
• Increased investment in mental health initiatives driving demand for innovative therapies.

What Are the Key Risks for BWAY?

Rich valuation — a P/E of 79.3 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.

• Regulatory challenges that could delay product approvals and market entry.
• Intense competition from established medical device manufacturers impacting market share.
• Economic downturns affecting healthcare spending and investment in mental health solutions.
• Technology advancements by competitors that may outpace BrainsWay's offerings.

What Are the Growth Opportunities for BWAY?

• Expansion into new markets: BrainsWay is poised to expand its footprint in emerging markets where mental health awareness is increasing. With a growing population and rising healthcare expenditure, regions such as Asia-Pacific present significant opportunities for growth. The global mental health market is expected to reach $537 billion by 2030, providing a substantial addressable market for BrainsWay's innovative therapies.
• Product line diversification: The company is actively developing new applications for its dTMS technology, targeting additional mental health disorders and chronic pain conditions. By expanding its product offerings, BrainsWay can tap into new revenue streams and enhance its market share within the mental health treatment sector.
• Strategic partnerships: Collaborating with healthcare providers and research institutions can enhance BrainsWay's credibility and facilitate clinical trials for new therapies. Such partnerships can accelerate product development timelines and improve market penetration, positioning the company favorably against competitors.
• Regulatory advancements: As regulatory bodies increasingly recognize the efficacy of noninvasive treatments for mental health disorders, BrainsWay could benefit from expedited approval processes for its products. This would allow the company to bring its therapies to market more quickly, capturing demand ahead of competitors.
• Increased investment in mental health: With a growing societal focus on mental health, governments and private sectors are increasing funding for innovative treatment solutions. BrainsWay stands to benefit from this trend, as increased investment can lead to greater adoption of its therapies across healthcare systems.

What Are BWAY's Competitive Advantages?

• Proprietary dTMS technology that differentiates BrainsWay from competitors.
• Strong intellectual property portfolio protecting its innovations.
• Established relationships with healthcare providers enhance customer loyalty.
• High gross margins indicate a premium pricing strategy and strong demand.
• Ongoing research and development efforts keep the company at the forefront of innovation.

What Does BWAY Do?

Founded in 2003 and headquartered in Jerusalem, Israel, BrainsWay Ltd. is a pioneering healthcare company that develops and markets noninvasive neurostimulation treatments aimed at addressing various mental health disorders. The company is recognized for its innovative Deep Transcranial Magnetic Stimulation (dTMS) platform technology, which is designed to treat a spectrum of conditions, including major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay's primary clientele consists of doctors, hospitals, and medical centers specializing in psychiatry, enabling the company to establish a solid foothold in the global healthcare market. With operations extending across the United States, Europe, Israel, and other international markets, BrainsWay is positioned to capitalize on the growing demand for effective mental health treatments. The company's commitment to research and development has fostered a robust pipeline of innovative therapies, enhancing its competitive edge in the medical devices industry. As mental health issues continue to rise globally, BrainsWay's focus on noninvasive solutions places it at the forefront of addressing these critical healthcare challenges.

What Products and Services Does BWAY Offer?

• Develops noninvasive neurostimulation treatments for mental health disorders.
• Offers a Deep Transcranial Magnetic Stimulation (dTMS) platform technology.
• Targets a variety of conditions including depression, PTSD, and chronic pain.
• Serves healthcare providers such as doctors, hospitals, and medical centers.
• Operates in multiple international markets including the U.S. and Europe.
• Focuses on innovative therapies to meet the growing demand for mental health solutions.

How Does BWAY Make Money?

• Generates revenue through the sale of dTMS systems and treatment services.
• Offers training and support to healthcare providers using its technology.
• Engages in research and development to expand its product offerings.
• Collaborates with medical institutions for clinical trials and studies.
• Licenses technology and intellectual property to third-party developers.

What Industry Does BWAY Operate In?

The medical devices industry, particularly in the mental health segment, is witnessing significant growth driven by increasing awareness of mental health issues and the demand for innovative treatment solutions. The global mental health market is projected to grow substantially, with a focus on noninvasive therapies gaining traction. BrainsWay Ltd. operates within this expanding landscape, competing against established players while capitalizing on its unique technology. The rise of telehealth and digital therapeutics also presents opportunities for companies like BrainsWay to enhance patient access and treatment adherence, further solidifying their market position.

Who Are BWAY's Key Customers?

• Psychiatrists and mental health professionals seeking innovative treatment options.
• Hospitals and medical centers looking to enhance their mental health services.
• Patients suffering from various mental health disorders requiring effective therapies.
• Healthcare systems aiming to improve patient outcomes and reduce costs.
• Research institutions conducting studies on neurostimulation and mental health.

BrainsWay Ltd. (BWAY) Valuation Context

Valued at $595M, BWAY is classified as a small-cap stock. Relative to its peer group, BWAY's quantitative score of 66/100 is roughly in line with the peer average of 74/100.

BWAY Revenue & Earnings Trend

In Q2 2026, BWAY generated $17.4M in top-line revenue, marking a sequential increase of 12.0%. The company recorded net income of $2.8M, with diluted EPS of $0.14. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this small-cap Healthcare company. Across the four most recent quarters, BWAY averaged $0.11 in diluted EPS.

Company Profile

BrainsWay Ltd. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Jerusalem, IL. The company is led by CEO Hadar Levy. BWAY has traded publicly since 2019.

Return on equity for BrainsWay Ltd. stands at 12.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 7.5%, showing how much profit it generates from its asset base. BWAY trades at a trailing price-to-earnings ratio of 79.33, above the Healthcare sector average of ~23x. Its free cash flow yield is 1.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.34 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 1.6%, the inverse of the P/E and a quick read on earnings relative to price.

BrainsWay Ltd.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 8.66 places it in the safe zone, indicating low near-term bankruptcy risk.

BrainsWay Ltd. has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 94.0% above estimates on average.

Wall Street analysts project BrainsWay Ltd. revenue of about $67.6M for fiscal 2026, with EPS near $0.31.

BWAY Financials

BWAY Latest News

BWAY Analyst Consensus

BWAY MoonshotScore

What Investors Ask About BrainsWay Ltd. (BWAY) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources